VivoSeq
Oncology

Brain Metastases

6

Pipeline Programs↗

33

Active Trials↗

13

Companies Involved↗

Brain Metastases is an early-stage landscape with 6 programs across 13 companies. The most active players are Sichuan Baili Pharmaceutical Co., Ltd., Roche, Pfizer.

Intelligence

Pipeline Metrics

Competitive Density

47/100

Pipeline Velocity

25/100

Mech. Concentration

20/100

Completion Rate

64/100

Attrition Rate

16/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

S

Sichuan Baili Pharmaceutical Co., Ltd.

1 program

Phase 2Roche logo

Roche

1 program

Phase 2Pfizer logo

Pfizer

1 program

Phase 2AbbVie logo

AbbVie

1 program

Phase 2Merck & Co. logo

Merck & Co.

1 program

Phase 2B

Betta Pharmaceuticals Co., Ltd.

0 programs

Preclinical

Pipeline

Programs by Phase

Preclinical
No programs
Phase 1
No programs
Phase 26

Trastuzumab

Organon and Co

T-DM1

Sichuan Baili Pharmaceutical Co., Ltd.

Pertuzumab

Roche

Tucatinib

Pfizer

Memantine

AbbVie

Phase 3
No programs
Approved
No programs

Analysis

Modality Breakdown

6programs
Small molecule350%
Monoclonal antibody350%

Modality classified for 100% of 6 pipeline programs.

Analysis

Trial Status

94

clinical trials

Completed28 · 30%
Unknown status17 · 18%
Recruiting16 · 17%
Terminated11 · 12%
Active, not recruiting10 · 11%
Not yet recruiting7 · 7%
Other5 · 5%

Clinical Trials

Trial Activity

94 trials

Early or Delayed Intervention of Brain Radiotherapy Combined With Almonertinib in EGFR Mutated NSCLC With Brain Metastases
Recruiting·SSun Yat-sen University·Phase 3·NCT05768490·232 enrolled
Phase II Trial of the PARP Inhibitor Niraparib and PD-1 Inhibitor Dostarlimab in Patients With Advanced Cancers With Active Progressing Brain Metastases (STARLET)
Recruiting·MM.D. Anderson Cancer Center·Phase 2·NCT05700721·120 enrolled
NTS-WBRT in Brain Metastases
Recruiting·MMassachusetts General Hospital·Phase 2·NCT05013892·41 enrolled
Assess Use of 18F-Fluciclovine for Patients With Large Brain Metastases Treated With Staged Stereotactic Radiosurgery
Recruiting·BBaptist Health South Florida·Phase 1·NCT04689048·20 enrolled
Adagrasib + SRS for Patients With Metastatic KRAS G12C-mutated NSCLC With Untreated Brain Metastases
Recruiting·—·Phase 2·NCT06248606·30 enrolled
Phase II Study of Pembrolizumab in Combination With Lenvatinib in Patients With TNBC, NSCLC, and Other Tumor Types and Brain Metastases
Recruiting·MM.D. Anderson Cancer Center·Phase 2·NCT05064280·104 enrolled
Phase 2b Imaging Study of RAD101 in Participants With Suspected Recurrent Brain Metastases
Recruiting·RRadiopharm Theranostics, Ltd·Phase 2·NCT06777433·30 enrolled
Reducing the Incidence of Symptomatic Brain Metastases With MRI Surveillance
Recruiting·WWake Forest University Health Sciences·Phase 2·NCT05692635·60 enrolled
Real-world Study of Taletrectinib for Advanced ROS1+ NSCLC With Brain Metastases
Recruiting·Innovent Biologics (Suzhou) Co. Ltd. logoInnovent Biologics (Suzhou) Co. Ltd.·N/A·NCT07008287·100 enrolled
REMASTer: REcurrent Brain Metastases After SRS Trial
Recruiting·MMonteris Medical·N/A·NCT05124912·261 enrolled
TY-9591 in the Patients With EGFR Mutations in Advanced NSCLC With Brain Metastases
Recruiting·TTYK Medicines, Inc·Phase 2·NCT05948813·420 enrolled
Sacituzumab Govitecan and Bevacizumab for NSCLC Brain Metastases
Recruiting·MMaastricht University Medical Center·Phase 2·NCT06401824·25 enrolled
SGM-101 in Colorectal Brain Metastases.
Recruiting·LLeiden University Medical Center·Phase 2·NCT04755920·10 enrolled
Phase I Study of Stereotactic Radiosurgery Dose Escalation for Brain Metastases
Recruiting·UUniversity of Utah·Phase 1·NCT02390518·86 enrolled
Ex Vivo Drug Response Evaluation for Next Generation Care of Brain Metastases
Recruiting·UUniversity of Zurich·Phase 2·NCT06620380·102 enrolled
Page 1 of 7

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)